DCGI gives Dr.Reddy’s approval, Sputnik V to go trial in India

  • Dr. Reddy’s, after having their first proposal rejected by the Drug Controller General of India, have now received an approval from the DCGI for conducting trials.

  • This done, the Sputnik V Vaccine for the COVID-19 will now be allowed to go for phase 2/3 human trial in India, which is the vaccine being generated by Russia.

  • “This will be a multi-center and randomized controlled study, which will include safety and immunogenicity study,” a joint statement issued by Dr Reddy’s and Russian Direct Investment Fund (RDIF) said.

  • Earlier, the DGCI raised its doubts because Sputnik V was tested on a small population in Russia before being registered as a vaccine, due to which it wasn’t conceived of its effectiveness.

D9D318A1-A861-4CFD-94ED-B72F5EDD67F3_edi

Subscribe to us

Thanks for submitting!

intern%20with%20us_edited.jpg
  • Instagram
  • Twitter
  • LinkedIn
  • Facebook

INDEPENDENT.

OBJECTIVE.

UNBIASED. 

the breif bulletin logo